dirucotide + Placebo
Phase 2/3Completed 0 watching 0 views this week📈 Rising
65
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Secondary Progressive Multiple Sclerosis
Conditions
Secondary Progressive Multiple Sclerosis
Trial Timeline
Dec 1, 2004 → May 1, 2009
NCT ID
NCT00869726About dirucotide + Placebo
dirucotide + Placebo is a phase 2/3 stage product being developed by Eli Lilly for Secondary Progressive Multiple Sclerosis. The current trial status is completed. This product is registered under clinical trial identifier NCT00869726. Target conditions include Secondary Progressive Multiple Sclerosis.
Hype Score Breakdown
Clinical
22
Activity
15
Company
10
Novelty
7
Community
8
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00869986 | Phase 2/3 | Completed |
| NCT00869726 | Phase 2/3 | Completed |
Competing Products
20 competing products in Secondary Progressive Multiple Sclerosis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| ASP7991 + Cinacalcet + Placebo | Astellas Pharma | Phase 2 | 52 |
| Fycompa | Eisai | Pre-clinical | 23 |
| Fycompa | Eisai | Pre-clinical | 23 |
| KHK7580 + KRN1493 | Kyowa Kirin | Phase 2/3 | 65 |
| KHK7580 | Kyowa Kirin | Phase 1 | 33 |
| KHK7580 | Kyowa Kirin | Phase 3 | 77 |
| KHK7580 | Kyowa Kirin | Phase 3 | 77 |
| Cinacalcet HCl | Kyowa Kirin | Approved | 85 |
| KHK7580 + Cinacalcet Hydrochloride | Kyowa Kirin | Phase 3 | 77 |
| Placebo + KHK7580 low dose + KHK7580 middle dose + KHK7580 high dose + KRN1493 | Kyowa Kirin | Phase 2 | 52 |
| dirucotide | Eli Lilly | Phase 2/3 | 65 |
| Paricalcitol + Calcitriol | AbbVie | Pre-clinical | 23 |
| paricalcitol + maxacalcitol + paricalcitol placebo + maxacalcitol placebo | AbbVie | Phase 3 | 77 |
| Paricalcitol + Calcifediol | AbbVie | Approved | 85 |
| Paricalcitol + Darbepoetin alfa | AbbVie | Approved | 85 |
| Birabresib Dose 20 mg | Merck | Phase 1 | 33 |
| Remibrutinib (blinded) + Placebo + Remibrutinib (Open label) | Novartis | Phase 3 | 77 |
| Ranibizumab | Novartis | Approved | 85 |
| BAF312 + Baseline disease modifying therapies (DMTs) + BNT162 + mRNA-1273 | Novartis | Approved | 85 |
| Ranibizumab 0.5mg + Ranibizumab 0.5 mg + Verteporfin PDT | Novartis | Phase 3 | 77 |